Compositions and methods for treatment
AssigneeSarcode Bioscience Inc.
InventorsThomas Gadek, John Burnier
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Claims25
-101. (canceled)
A method of modulating the interaction between (i) a member selected from the group consisting of CD11a, CD18, or a combination thereof and (ii) an intercellular adhesion molecule selected from the group consisting of ICAM-1, ICAM-2, and ICAM-3, or any combination of any of the foregoing, in a patient in need of such modulation, said method comprising administering to said patient a modulation effective amount of the compound
- or a pharmaceutically acceptable salt thereof.
A method of modulating the interaction between (i) a member selected from the group consisting of CD11a, CD18, or a combination thereof and (ii) an intercellular adhesion molecule selected from the group consisting of ICAM-1, ICAM-2, and ICAM-3, or any combination of any of the foregoing, in a patient in need of such modulation, said method comprising administering to said patient a modulation effective amount of the compound
- or a pharmaceutically acceptable salt thereof, whereby said administration is effective in promoting tear secretion or mucin production in said eye in said patient, and wherein said patient does not have Sjogren's syndrome.
A method of modulating the interaction between (i) a member selected from the group consisting of CD11a, CD18, or a combination thereof and (ii) an intercellular adhesion molecule selected from the group consisting of ICAM-1, ICAM-2, and ICAM-3, or any combination of any of the foregoing, in a patient in need of such modulation, said method comprising administering to said patient a modulation effective amount of the compound
- or a pharmaceutically acceptable salt thereof, whereby said administration is effective in promoting tear secretion or mucin production in said eye in said patient, and wherein said patient has Sjogren's syndrome.
A method of modulating the interaction between (i) a member selected from the group consisting of CD11a, CD18, or a combination thereof and (ii) an intercellular adhesion molecule selected from the group consisting of ICAM-1, ICAM-2, and ICAM-3, or any combination of any of the foregoing, in a patient in need of such modulation, said method comprising performing a dry eye diagnostic test on said patient;
- determining whether said patient suffers from a dry eye disease based on the results of said diagnostic step;
- and upon diagnosis of said dry eye disease, administering to said patient a modulation effective amount of the compound
- or a pharmaceutically acceptable salt thereof, and wherein said patient does not have Sjogren's syndrome.
A method of modulating the interaction between (i) a member selected from the group consisting of CD11a, CD18, or a combination thereof and (ii) an intercellular adhesion molecule selected from the group consisting of ICAM-1, ICAM-2, and ICAM-3, or any combination of any of the foregoing, in a patient in need of such modulation, said method comprising performing a dry eye diagnostic test on said patient;
- determining whether said patient suffers from a dry eye disease based on the results of said diagnostic step;
- and upon diagnosis of said dry eye disease, administering to said patient a modulation effective amount of the compound
- or a pharmaceutically acceptable salt thereof, and wherein said patient has Sjogren's syndrome.
Dependencies are inferred from the claim text.